CEO Viehbacher Confident In Biogen’s Portfolio, But Open To Additions

Q4 Revenue In Line, Guidance Below Consensus

 
• By Mandy Jackson
  
Biogen's Q4 sales were up 3% from Q4 2023, but full-year 2024 sales were down 2% (Shutterstock)

More from Earnings

More from Scrip